Citations

Clear

6274 citation(s) found for "To, Andrew".

Influence Of A Multi-ingredient Pre-workout Supplement On Energy Expenditure, Oxygen Uptake, And Subjective Feelings Of Fatigue During Low-intensity Aerobic Exercise
Stefan, Riley R., Lutsch, Daniel J., Hill, Chris , Camic, Clayton L., Jagim, Andrew R. , Hill, Chris M.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 287-288

10.1249/01.mss.0000762452.62307.d8 Get It

Sport Nutrition Knowledge And Perceptions Of Dietary Requirements Among A Diverse Cohort Of Collegiate Athletes.
Luedke, Joel, Erickson, Jacob L. , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 273-274

10.1249/01.mss.0000762268.93478.76 Get It

Management of Congenital Long-QT Syndrome: Commentary From the Experts
Kaufman, Elizabeth S. , Eckhardt, Lee L. , Ackerman, Michael J. , Aziz, Peter F. , Behr, Elijah R. , Cerrone, Marina , Chung, Mina K. , Cutler, Michael J. , Etheridge, Susan P. , Krahn, Andrew D. , Lubitz, Steven A. , Priori, Silvia G. , Roberts, Jason D. , Roden, Dan M. , Schulze‐Bahr, Eric , Shoemaker, M. Benjamin , Sy, Raymond W. , Towbin, Jeffrey A. , Wilde, Arthur A.M. , Zaręba, Wojciech , Behr, Elijah Raphael , Eckhardt, Lee L , Krahn, Andrew D , Lubitz, Steven A , Cerrone, Marina , Zareba, Wojciech , Priori, Silvia , Pérez, Marco , Roden, Dan M. , Schwartz, Peter J. , Shimizu, Wataru , Viskin, Sami

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 9, 2021 | Volume: 14 | Issue: 7 | Pages: No page available

10.1161/circep.120.009726 | PMID 34238011 Get It

While published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
Semb, Anne Grete , Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joseph, Crowson, Cindy S., Riel, Piet L. C. M. van , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Durez, Patrick , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Douglas, Karen, Agarwal, Vikas , Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Kerola, Anne M , Crowson, Cindy, Karpouzas, George Athanasios , Gonzalez-Gay, Miguel A , Tektonidou, Maria G , Durez, Patrick , Pascual-Ramos, Virginia , Galarza-Delgado, Dionicio Angel , Misra, Durga Prasanna , Agarwal, Vikas , Valentinovna Popkova, Tatiana , Semb, Anne Grete , Kitas, George D. , Graham, Ian , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Faggiano, Pompilio Massimo , Vrablı́k, Michal

Mayo Clinic

RMD Open | July 8, 2021 | Volume: 7 | Issue: 2 | Pages: e001724

10.1136/rmdopen-2021-001724 | PMID 34244381 Get It

Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014–2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .
Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma
Anderson, Nicole , Qin, Xiaodan , Finan, Jennifer M. , Lam, Andrew , Athoe, Jacob, Missiaen, Rindert , Skuli, Nicolas , Kennedy, Annie, Saini, Amandeep S. , Tao, Ting , Zhu, Shizhen , Nissim, Itzhak , Look, A. Thomas , Qing, Guoliang , Simon, M. Celeste , Feng, Hui , Tao, Ting , Anderson, Nicole M., Kennedy, Annie

Mayo Clinic

Cancer Research | July 7, 2021 | Volume: 81 | Issue: 17 | Pages: 4417-4430

10.1158/0008-5472.can-20-2153 | PMID 34233924 Get It

Abstract High-risk neuroblastoma remains therapeutically challenging to treat, and the mechanisms promoting disease aggression are poorly understood. Here, we show that elevated expression of dihydrolipoamide S-succinyltransferase (DLST) predicts poor treatment outcome and aggressive disease in patients with neuroblastoma. DLST is an E2 component of the α-ketoglutarate (αKG) dehydrogenase complex, which governs the entry of glutamine into the tricarboxylic acid cycle (TCA) for oxidative decarboxylation. During this irreversible step, αKG is converted into succinyl-CoA, producing NADH for oxidative phosphorylation (OXPHOS). Utilizing a zebrafish model of MYCN-driven neuroblastoma, we demonstrate that even modest increases in DLST expression promote tumor aggression, while monoallelic dlst loss impedes disease initiation and progression. DLST depletion in human MYCN-amplified neuroblastoma cells minimally affected glutamine anaplerosis and did not alter TCA cycle metabolites other than αKG. However, DLST loss significantly suppressed NADH production and impaired OXPHOS, leading to growth arrest and apoptosis of neuroblastoma cells. In addition, multiple inhibitors targeting the electron transport chain, including the potent IACS-010759 that is currently in clinical testing for other cancers, efficiently reduced neuroblastoma proliferation in vitro. IACS-010759 also suppressed tumor growth in zebrafish and mouse xenograft models of high-risk neuroblastoma. Together, these results demonstrate that DLST promotes neuroblastoma aggression and unveils OXPHOS as an essential contributor to high-risk neuroblastoma. Significance: These findings demonstrate a novel role for DLST in neuroblastoma aggression and identify the OXPHOS inhibitor IACS-010759 as a potential therapeutic strategy for this deadly disease.
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joe , Crowson, Cynthia S. , Riel, Piet L. C. M. van , Graham, Ian , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Graham, Ian , Tektonidou, Maria G , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Kitas, George D. , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Durez, Patrick , Faggiano, Pompilio Massimo , Valentinovna Popkova, Tatiana , Vrablı́k, Michal , Semb, Anne Grete

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | July 5, 2021 | Volume: 8 | Issue: 6 | Pages: 539-548

10.1093/ehjcvp/pvab052 | PMID 34232315 Get It

Abstract Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014–19. The treatment goal for BP was &lt;140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease
Keret, Ophir , Staffaroni, Adam M. , Ringman, John M. , Goh, Sheng‐Yang M., Wolf, Amy , Allen, Isabel Elaine , Salloway, Stephen , Chhatwal, Jasmeer P. , Reyes‐Dumeyer, Dolly , Bateman, Randall J. , Morris, John C. , Joseph‐Mathurin, Nelly , Perrin, Richard J. , Gordon, Brian A. , Xiong, Chengjie , Vöglein, Jonathan , Fougère, Christian la , Martins, Ralph N. , Sohrabi, Hamid R. , Taddei, Kevin , Villemagne, Victor L. , Fulham, Michael , Masters, Colin L. , Saykin, Andrew J. , Graff‐Radford, Neill R. , Weiner, Michael W. , Cash, David M. , Chrem, Patricio, Rabinovici, Gil D. , Rosen, Howard J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Saykin, Andrew J , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Morris, John C , Cash, David M , Rabinovici, Gil D , Cobigo, Yann , Brickman, Adam M. , Benzinger, Tammie L.S. , Ances, Beau M. , Jucker, Mathias , Schofield, Peter R. , Brooks, William S. , Ghetti, Bernardino , Jack, Clifford R. , Allegri, Ricardo , Su, Yi , Miller, Bruce L. , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 5, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12197 | PMID 34258377 Get It

Abstract Introduction Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD‐MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD‐MC and could help predict risk for dementia during trial enrollment. Methods We created a dementia risk score by entering standardized gray‐matter volumes from 231 DIAD‐MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD‐MC followed longitudinally. Results Our risk score separated asymptomatic versus demented DIAD‐MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD‐MC participants for prevention trials.
Abstract TP85: Screening Individuals with Intracranial Aneurysms for Abdominal Aortic Aneurysms is Cost-Effective Based on Estimated Co-prevalence
Ball, Benjamin Z., Stukenborg, George J., Luke, Sothear H., Worrall, Bradford B. , Southerland, Andrew M. , Upchurch, Gilbert R. , Meschia, James F.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.atp85 Get It

Introduction: Abdominal aortic aneurysm (AAA) rupture is associated with high mortality and morbidity. The U.S. Preventive Services Task Force recommends one-time ultrasound screening for AAA in men age 65-75 who have ever smoked. Little is known about other high-risk subpopulations. Recent linkage and genome-wide association studies confirm a shared genetic risk between AAA and intracranial aneurysms (IA). We tested the hypothesis that sonographic screening for AAA in individuals known to have IA is cost-effective. Methods: A decision tree model was developed to compare costs and outcomes of AAA screening compared to no screening in a hypothetical cohort of patients with IA. Event probabilities, utilities, and costs included in the model were derived through a comprehensive literature review. Expected outcomes of screening vs. no screening were measured in terms of quality-adjusted life years (QALY), lifetime costs and the overall cost-effectiveness ratio. Sensitivity analyses were performed to assess the effects of ranging baseline variables, within plausible minimum and maximum values, on model outcomes, as well as to identify thresholds of model variables where a decision alternative was dominated (both more expensive and less effective than the alternative). Results: In our base-case analysis, screening for AAA provided an additional 0.1055 QALYs (28.1521-screening, 28.0466-no screening) at an additional lifetime cost of $3.62 ($374.57-screening and $370.95-no screening). This yielded an incremental cost-effectiveness ratio (ICER) of $34.31/QALY. In sensitivity analyses, a prevalence of AAA in the IA population ≥ 7.5%, sensitivity of ultrasound screening ≥ 91%, or extrapolating the risk of AAA rupture to 6 years each caused the screening arm to dominate the model. Conclusion: Based on this model, screening for AAA in individuals with IA is cost-effective with an ICER of $34.31/QALY. This is well below accepted societal thresholds estimated to be less than $50,000/QALY. The sensitive variables in the model, particularly co-prevalence of IA and AAA, favored screening within conservative estimates from the literature. Prospective study evaluating the co-prevalence of IA and AAA will further elucidate the value of dedicated screening.
Abstract TMP49: Yield of Diagnostic Evaluation in Major Stroke Phenoytypes
Brown, Robert D. , Grewal, Raji P., Jiménez-Conde, Jordi , Kittner, Steven J. , Peddareddygari, Leema Reddy , Rhodes, J. , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Ay, Hakan , investigators, for the NINDS Stroke Genetics Network (SiGN), Majersik, Jennifer Juhl , Arsava, Ethem Murat , Jern, Christina , Jood, Katarina , Labovitz, Daniel , Lindgren, Arne G. , Meschia, James F. , Pera, Joanna , Rosand, Jonathan M. , Rundek, Tatjana , Southerland, Andrew M. , investigators, for the NINDS Stroke Genetics Network (SiGN)

Mayo Clinic

Stroke | July 3, 2021 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.atmp49 Get It

Background: Considerable disagreement exists among experts regarding the appropriate extent of diagnostic testing after ischemic stroke (IS). Evidence-based data guiding stroke evaluation for individual patients according to the underlying phenotype are unknown. We sought to determine the yield of cardiac and arterial evaluations for identifying an alternative major stroke etiology in patients with a given phenotype in the NINDS Stroke Genetics Network (SiGN). Methods: SiGN is a consortium of IS studies at 22 US and European sites aiming to identify stroke susceptibility genes. Adjudicators certified in Causative Classification of Stroke (CCS) system determined major etiologic stroke phenotypes based on chart review. All diagnostic data entered into the CCS software were stored in a confidential database. We determined the probability of identifying an alternative major abnormality based on cardiac (history, EKG, echocardiography) and arterial [intracranial (IC), extracranial (EC)] evaluations in 3 stroke phenotypes: lacunar infarct (LI), large artery atherosclerosis (LAA), and cardiac embolism (CE). Proportions of alternative major etiologies were calculated in patients with complete evaluations in each phenotype. Results: The analyses included 15720 patients. Among these, 2299 had phenotypic subtype of LI (1660 with cardiac and 1691 with arterial evaluations); 4228 had CE (2451 with arterial evaluation); and 2613 had LAA (2047 with cardiac evaluation). Cardiac evaluation revealed a major cardiac source of embolism in 12.3% of patients with LI and 20.3% with LAA. Echocardiography demonstrated an additional major structural cardiac source not seen by history/examination/EKG in 1.9% and 1.6% in LI and LAA respectively. Arterial evaluation led to the identification of ≥50%ipsilateral stenosis in 13.5% (IC: 8.9%, EC: 5.8%) of patients with LI and 17% (IC: 8.1%, EC: 11.3%) of those with CE. In LI patients with complete cardiac and vascular evaluations, 24.1% had an alternative major stroke etiology. Conclusions: A considerable proportion of IS patients with LI, LAA, and CE harbor an alternative major etiology. In the future, these results can be used to generate evidence-based and cost-effective evaluation and management strategies.
Abstract 3884: Stroke Subtypes in Hispanic Patients in the NINDS Stroke Genetics Network (SiGN): A Comparison of Two Classification Systems
Katsnelson, Michael , Gardener, Hannah , Malik, Shaneela , Brown, Robert D. , Barrett, Kevin M. , Ossi, Raid G., Biffi, Alessandro , Helenius, Joanna, Huq, Mohammed Saiful, Weissman, Darren, Sheikh, Huma U., Saraf, Neha, Peddareddygari, Leema Reddy , Woo, Daniel , Smoller, Sylvia, Grewal, Raji P., Worrall, Bradford B. , Ay, Hakan , Kittner, Steven J. , Rundek, Tatjana , Sacco, Ralph L. , Southerland, Andrew M. , Arsava, Ethem Murat , Rexrode, Kathryn M. , Huq, Mohammed, Labovitz, Daniel , Rhodes, David , Brenner, David A. , Rosand, Jonathan M. , Arnett, Donna K. , Meschia, James F.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a3884 Get It

Objectives: Identification of gene variants of stroke subtypes is important for the development of tailored ischemic stroke therapies among various ethnic groups. Valid and reliable determination of ischemic stroke subtype is essential for achieving this goal and to standardize a classification scheme across multi-center studies and different populations. Causative Classification System for Ischemic Stroke (CCS) is a novel computerized subclassification tool developed to improve reliability and accuracy of classifying stroke types. The CCS algorithm relies on both phenotypic and causative stroke variables. A Hispanic subset of the SiGN, an important and distinct target population with greater risk of certain stroke subtypes, was evaluated with Trial of Org 10172 in Acute Stroke Treatment (TOAST) and CCS and the agreement between the two classification systems was analyzed. Methods: Over 6000 subjects at 15 sites across US and Europe were enrolled, with TOAST and CCS locally adjudicated. Blood collection and central data quality control (10% central readjudication) were performed on all participants. A subset of Hispanics was analyzed for the purpose of this study and the agreement between the TOAST and CCS were assessed by kappa statistic. Findings: Hispanics (n=595, 10.9%) compared to non-Hispanics (n=5457) were more likely to be younger (63.7 vs. 64.0), male (55% vs. 46%) and have fewer of the traditional stroke risk factors HTN (54% vs. 64%), Afib (11% vs. 14%), DM(23% vs. 25%), CAD(16% vs. 20%) and smoking(19% vs. 22%). While the TOAST showed no differences between stroke subtypes for Hispanic vs. non-Hispanics, in CCS, Hispanics were classified with more of large vessel (22% vs. 20%), cardioembolic (37% vs. 30%) and small vessel strokes (13% vs. 9%) and fewer with undetermined etiology (28% vs. 40%) as compared to non-Hispanics. TOAST and CCS offered moderate correlation across all stroke types in Hispanics: kappa of 0.66 for large artery atherosclerosis, 0.58 for cardioembolic, and 0.58 for small artery occlusion. Conclusion: CCS offers a more sensitive and accurate system for subphenotyping of strokes in Hispanics who tended to have relatively fewer risk factors and unclassified strokes. Further studies correlating the two classification systems and their relation to genotyping data are warranted.